NCT03685448 - ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 11, 2019

Primary Completion Date

December 30, 2024

Study Completion Date

June 4, 2025

Conditions

Renal Cell CarcinomaPapillary Renal Cell Carcinoma Type 1Papillary Renal Cell Carcinoma Type 2Chromophobe Renal Cell CarcinomaSarcomatoid Renal Cell CarcinomaXp11.2 Translocation-Related Renal Cell Carcinoma

Interventions

DRUG

Cabozantinib

The 20 mg cabozantinib drug product is a film-coated, white, round, immediate-release tablet. Cabozantinib should not be stored above 25°C (77°F).

Trial Locations (11)

2109

Macquarie University Hospital, Macquarie Park

2460

Border Medical Oncology Research Unit / The Border Cancer Hospital, Albury

2560

Campbelltown Hospital, Campbelltown

3128

Box Hill Hospital - Eastern Health, Box Hill

3630

Goulburn Valley Health, as a satellite site under the supervision of Border Medical Oncology Research Unit, via the Tele-trial model, Shepparton

5037

Adelaide Cancer Centre / Ashford Cancer Centre Research / Cancer Care SA, Kurralta Park

5042

Flinders Medical Centre, Bedford Park

Unknown

St George Hospital, Kogarah

Calvary Mater Newcastle, Newcastle

Royal Brisbane & Women's Hospital, Herston

Monash Medical Centre, Clayton

All Listed Sponsors

lead

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

OTHER